Related Experiment Video
Updated: Jul 25, 2026
11:10
Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice
Published on: November 16, 2011
Novel thiazolidine-2,4-diones as potent euglycemic agents
B Hulin1, D A Clark, S W Goldstein
1Central Research, Pfizer Inc., Groton, Connecticut 06340.
Journal of Medicinal Chemistry
|May 15, 1992
Summary
Researchers developed novel thiazolidine-2,4-diones to combat high blood sugar. These compounds effectively reduced glucose levels in obese, insulin-resistant mice, showing promise for diabetes treatment.
Area of Science:
- Medicinal Chemistry
- Pharmacology
- Endocrinology
Background:
- Obesity and insulin resistance are significant global health challenges.
- Existing diabetes treatments have limitations, necessitating novel therapeutic approaches.
- Thiazolidine-2,4-diones are a known class of antidiabetic agents.
Purpose of the Study:
- To synthesize and evaluate a new series of thiazolidine-2,4-dione derivatives.
- To investigate the potential of these novel compounds in managing hyperglycemia.
- To explore structure-activity relationships for enhanced antidiabetic potency.
Main Methods:
- Chemical synthesis of novel thiazolidine-2,4-dione analogs.
- Modification of the englitazone scaffold by introducing ketone, alcohol, or olefin groups.
- In vivo assessment of glucose-lowering effects in ob/ob mice.
Main Results:
- The synthesized thiazolidine-2,4-dione derivatives demonstrated significant blood glucose-lowering activity.
- Compounds featuring an oxazole-based group exhibited particularly high potency.
- The modifications successfully altered the englitazone ether function, yielding active analogs.
Conclusions:
- Novel thiazolidine-2,4-dione derivatives are effective in reducing blood glucose in a model of obesity and insulin resistance.
- The strategic incorporation of specific functional groups, such as oxazole moieties, enhances antidiabetic efficacy.
- These findings support the development of new thiazolidine-2,4-dione-based therapies for type 2 diabetes.
Related Concept Videos
01:17Oral Hypoglycemic Agents: Sulfonylureas
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide (Glucotrol),...
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
01:06Oral Hypoglycemic Agents: Glinides
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Acarbose and miglitol are typically...
01:24Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
01:23Dipeptidyl Peptidase 4 Inhibitors
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...